

low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. *Haematologica*. 2014;99(9):e162-164.

- 13/ Lacy MQ¹, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. *Blood*. 2011 Sep 15;118(11):2970-5. doi: 10.1182/blood-2011-04-348896. Epub 2011 Jun 20.
- 14/ Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG.: Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. *J Clin Oncol*. 2011 May 10;29(14):1916-23. doi: 10.1200/JCO.2010.34.0760. Epub 2011 Apr 11.
- 15/ Palumbo A¹, Avet-Loiseau H¹, Oliva S¹, Lokhorst HM¹, et al.: Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *J Clin Oncol*. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
- 16/ Giralt S¹, Garderet L², Durie B³, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biol Blood Marrow Transplant*. 2015 Dec;21(12):2039-51. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.

2857. STATE OF THE ART 2016: DIAGNOSIS AND TREATMENT OF LIGHT CHAIN AMYLOIDOSIS

Schönland S. (*Medizinische Universitätsklinik, Universitätsklinikum, Heidelberg – D*)

Abstrakt sdělení není k dispozici.

WIEDERMANNOVA PŘEDNÁŠKA

2867. OHLÉDNUTÍ ZA 30 ROČNÍKY OHD, PRAVIDELNÉ HEMATOLOGICKÉ AKCE S NEJDELŠÍ TRADICÍ V ČR V KONTEXTU OLOMOUCKÉ HEMATOLOGIE

Indrák K. (*HOK, FN, Olomouc*)

Abstrakt sdělení není k dispozici.

2990. CHANGING LANDSCAPE OF ALLOGENEIC DONOR HEMATOPOIETIC CELL TRANSPLANTATION: IMPACT OF DONOR CHOICE, CONDITIONING AND DISEASE STATUS ON TRANSPLANT DECISIONS

Bachanová V. (*Division of Hematology, Oncology and Transplantation University of Minnesota, Minnesota – USA*)

The fundamental goal of successful allogeneic transplantation is to deliver potent immune mediated anti-tumor responses while mitigating graft-versus-host disease and infectious complications. Transplant-related mortality and relapse continue to be the largest hurdles facing patients following allograft. Recent advances and controversies using reduced intensity conditioning platform and alternative graft sources such as HLA-haploidentical related donors and umbilical cord blood to treat adult malignancies will be discussed. Disease status and minimal residual disease impacts on relapse and survival and should be considered in decision making particularly for acute leukemia. We will also exploit the evolving use of immunotherapeutic strategies including combinations of allograft with NK cell infusions, pathogen-specific T cells, Treg manipulations, and chimeric antibody receptor T cells.